Exited position

Daniel Loeb’s Gilead Sciences Inc (GILD) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Third Point LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2011Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares1.90MHighest verified quarter-end share count
Quarters reported4Verified quarters with shares above zero
What happened?

Third Point LLC first reported Gilead Sciences Inc in Q3 2011. The reported position was increased across later filings. The latest verified relationship event shows that Third Point LLC sold the entire position in Q1 2014, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q1 2014
Sold the entire position−1.50M shares · No shares reported at quarter-end
Q4 2013
Bought 200.0% more+1.00M shares · 1.50M shares reported after the change
Filing context

Quarter-end price $75.10 · Estimated holding basis $71.02

Q3 2013
New position+500.00K shares · 500.00K shares reported
Filing context

Quarter-end price $62.87 · Estimated holding basis $62.87

Q1 2012
Sold the entire position−1.90M shares · No shares reported at quarter-end
Q4 2011
Bought 58.3% more+700.00K shares · 1.90M shares reported after the change
Filing context

Quarter-end price $40.93 · Estimated holding basis $39.58

Q3 2011
New position+1.20M shares · 1.20M shares reported
Filing context

Quarter-end price $38.80 · Estimated holding basis $38.80

Portfolio importance

How important was Gilead Sciences Inc in Third Point LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight2.1%Q4 2013
Last reported rank#21of 39 reported positions
Peak portfolio weight3.2%Q4 2011
Best historical rank#7Q4 2011
At peak importanceQ4 2011
GILD
3.2%
Largest holding
36.7%
Cross-investor discovery

Who else owns Gilead Sciences Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Ray DalioBridgewater Associates, LP
GILD0.2% of reported portfolio
Joel GreenblattGotham Asset Management
GILD0.1% of reported portfolio
Explore Gilead Sciences Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$146.412026-09-14

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Third Point LLC’s Form 13F disclosures, not Daniel Loeb’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.